Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033

February 2024 | 104 pages | ID: A350048DAB59EN
BIS Research Inc.

Abstracts

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

This report will be delivered in 1-5 working days.

Introduction to Asia-Pacific Rare Disease Genetic Testing Market

The Asia-Pacific rare disease genetic testing market was valued at $0.58 billion in 2023 and is anticipated to reach $2.40 billion by 2033, witnessing a CAGR of 15.25% during the forecast period 2023-2033. Advanced technologies like whole-genome sequencing (WGS) and whole-exome sequencing (WES) analyze an individual's entire genetic code (genome) or specific protein-coding regions (exome), respectively. They aid in detecting genetic variations, mutations, or abnormalities linked to rare diseases.

Market Introduction

The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors. Increased awareness, advancements in genetic testing technologies, and rising healthcare expenditure contribute to market expansion. Moreover, the region's large population base and diverse genetic profiles present significant opportunities for genetic testing providers. Government initiatives aimed at improving healthcare infrastructure and expanding access to genetic testing services further propel market growth. Additionally, collaborations between healthcare organizations, research institutions, and industry players facilitate the development and adoption of innovative genetic testing solutions tailored to the region's specific needs. With a growing focus on precision medicine and personalized healthcare, the APAC rare disease genetic testing market is poised for continued expansion and innovation in the foreseeable future.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Japan
• India
• China
• South Korea
• Australia
• Singapore
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The APAC rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The APAC rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• 3billion, Inc.
• Konica Minolta (Ambry Genetics, Inc.)
• BGI Group
• Strand Life Science Pvt Ltd.

Contents

Executive Summary
Scope of the Study
Research Methodology

1 MARKET

1.1 Market Outlook
  1.1.1 Product Definition
  1.1.2 Inclusion and Exclusion Criteria
    1.1.2.1 Inclusion Criteria
    1.1.2.2 Exclusion Criteria
  1.1.3 Market Overview
    1.1.3.1 Market Footprint
    1.1.3.2 Market Size and Future Growth Potential
  1.1.4 COVID-19 Impact on the Market
    1.1.4.1 Impact on Research and Clinical Operations
    1.1.4.2 COVID-19 Impact: Current Scenario of the Market
1.2 Industry Analysis
  1.2.1 Regulatory Framework
    1.2.1.1 Legal Requirements and Framework in Asia-Pacific
      1.2.1.1.1 Japan
      1.2.1.1.2 China
      1.2.1.1.3 India
      1.2.1.1.4 Taiwan
  1.2.2 Patent Analysis
    1.2.2.1 Patent Filing Trend (by Country)
    1.2.2.2 Patent Filing Trend (by Year)
  1.2.3 Funding Scenario
1.3 Market Dynamics
  1.3.1 Overview
  1.3.2 Market Drivers
    1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  1.3.3 Market Challenges
    1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  1.3.4 Market Opportunities
    1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 RARE DISEASE GENETIC TESTING MARKET (BY REGION)

2.1 Asia-Pacific Rare Disease Genetic Testing Market
  2.1.1 Market Dynamics
    2.1.1.1 Impact Analysis
  2.1.2 Market Size and Forecast
    2.1.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
    2.1.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
    2.1.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
      2.1.2.3.1 Japan
        2.1.2.3.1.1 Market Dynamics
        2.1.2.3.1.2 Market Size and Forecast
          2.1.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.2 China
        2.1.2.3.2.1 Market Dynamics
        2.1.2.3.2.2 Market Size and Forecast
          2.1.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.3 Australia
        2.1.2.3.3.1 Market Dynamics
        2.1.2.3.3.2 Market Size and Forecast
          2.1.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.4 South Korea
        2.1.2.3.4.1 Market Dynamics
        2.1.2.3.4.2 Market Size and Forecast
          2.1.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.5 India
        2.1.2.3.5.1 Market Dynamics
        2.1.2.3.5.2 Market Size and Forecast
          2.1.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.6 Singapore
        2.1.2.3.6.1 Market Dynamics
        2.1.2.3.6.2 Market Size and Forecast
          2.1.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
      2.1.2.3.7 Rest-of-Asia-Pacific
        2.1.2.3.7.1 Market Dynamics
        2.1.2.3.7.2 Market Size and Forecast
          2.1.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
          2.1.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)

3 COMPANY PROFILES

3.1 Overview
  3.1.1 3billion, Inc.
    3.1.1.1 Company Overview
    3.1.1.2 Role of 3billion, Inc. in the Rare Disease Genetic Testing Market
    3.1.1.3 Recent Developments
    3.1.1.4 Analyst Perspective
  3.1.2 Konica Minolta (Ambry Genetics, Inc.)
    3.1.2.1 Company Overview
    3.1.2.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Rare Disease Genetic Testing Market
    3.1.2.3 Financials
    3.1.2.4 Recent Developments
    3.1.2.5 Analyst Perspective
  3.1.3 BGI Group
    3.1.3.1 Company Overview
    3.1.3.2 Role of BGI Group in the Rare Disease Genetic Testing Market
    3.1.3.3 Financials
    3.1.3.4 Recent Developments
    3.1.3.5 Analyst Perspective
  3.1.4 Strand Life Science Pvt Ltd.
    3.1.4.1 Company Overview
    3.1.4.2 Role of Strand Life Science Pvt Ltd. in the Rare Disease Genetic Testing Market
    3.1.4.3 Recent Developments
    3.1.4.4 Analyst Perspective

List Of Figures

LIST OF FIGURES

Figure 1: Prevalence Rare Disease, 2022
Figure 2: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 3: Rare Disease Genetic Testing Market, Market Dynamics
Figure 4: Most Frequently Studied Rare Diseases, 2021
Figure 5: Asia-Pacific Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
Figure 6: Asia-Pacific Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
Figure 7: Share of Key Developments and Strategies, January 2019-June 2023
Figure 8: Rare Disease Genetic Testing Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Asia-Pacific Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
Figure 13: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
Figure 14: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
Figure 15: NIH Funding on Rare Diseases, $Million, 2013-2023
Figure 16: Rare Disease Genetic Testing Market Dynamics
Figure 17: Rare Disease Prevalence in India, 2022
Figure 18: Prevalence of Rare Diseases, 2022
Figure 19: Most Frequently Studied Rare Diseases, 2021
Figure 20: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
Figure 21: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
Figure 22: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 23: Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 24: Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 25: Asia-Pacific Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
Figure 26: Japan Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 27: Japan Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 28: Japan Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 29: China Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 30: China Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 31: China Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 32: Australia Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 33: Australia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 34: Australia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 35: South Korea Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 36: South Korea Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 37: South Korea Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 38: India Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 39: India Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 40: India Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 41: Singapore Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 42: Singapore Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 43: Singapore Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 44: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 45: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 46: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 47: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
Figure 48: 3billion, Inc: Product Portfolio
Figure 49: Konica Minolta (Ambry Genetics, Inc.): Product Portfolio
Figure 50: Konica Minolta (Ambry Genetics, Inc.).: Overall Financials, $Million, 2020-2022
Figure 51: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Segment), $Million, 2020-2022
Figure 52: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Region), $Million, 2020-2022
Figure 53: Konica Minolta (Ambry Genetics, Inc.): R&D Expenditure, $Million, 2020-2022
Figure 54: BGI Genomics: Product Portfolio
Figure 55: BGI Genomics.: Overall Financials, $Million, 2020-2022
Figure 56: Strand Life Science Pvt Ltd.: Product Portfolio

List Of Tables

LIST OF TABLES

Table 1: Key Questions Answered in the Report
Table 2: Funding for Rare Disease Research
Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
Table 5: Asia-Pacific Rare Disease Genetic Testing Market, Impact Analysis